1. Cancer Biology
  2. Immunology and Inflammation

Human primed ILCPs support endothelial activation through NF-κB signaling

  1. Giulia Vanoni
  2. Giuseppe Ercolano
  3. Simona Candiani
  4. Mariangela Rutigliani
  5. Mariangela Lanata
  6. Laurent Derré
  7. Emanuela Marcenaro
  8. Pascal Schneider
  9. Pedro Romero
  10. Camilla Jandus  Is a corresponding author
  11. Sara Trabanelli  Is a corresponding author
  1. University of Lausanne - Ludwig Institute for Cancer Research, Switzerland
  2. University of Geneva, Switzerland
  3. University of Genova, Italy
  4. E.O. Galliera Hospital, Italy
  5. University Hospital of Lausanne (CHUV), Switzerland
  6. University of Lausanne, Switzerland
https://doi.org/10.7554/eLife.58838
Share this article
Cite this article
  1. Giulia Vanoni
  2. Giuseppe Ercolano
  3. Simona Candiani
  4. Mariangela Rutigliani
  5. Mariangela Lanata
  6. Laurent Derré
  7. Emanuela Marcenaro
  8. Pascal Schneider
  9. Pedro Romero
  10. Camilla Jandus
  11. Sara Trabanelli
(2021)
Human primed ILCPs support endothelial activation through NF-κB signaling
eLife 10:e58838.
https://doi.org/10.7554/eLife.58838
  2. Download BibTeX
  3. Download .RIS

Abstract

Innate lymphoid cells (ILCs) represent the most recently identified subset of effector lymphocytes, with key roles in the orchestration of early immune responses. Despite their established involvement in the pathogenesis of many inflammatory disorders, the role of ILCs in cancer remains poorly defined. Here we assessed whether human ILCs can actively interact with the endothelium to promote tumor growth control, favoring immune cell adhesion. We show that, among all ILC subsets, ILCPs elicited the strongest upregulation of adhesion molecules in ECs in vitro, mainly in a contact-dependent manner through the TNFR- and RANK-dependent engagement of the NF-κB pathway. Moreover, the ILCP-mediated activation of the ECs resulted to be functional by fostering the adhesion of other innate and adaptive immune cells. Interestingly, pre-exposure of ILCPs to human tumor cell lines strongly impaired this capacity. Hence, the ILCP-EC interaction might represent an attractive target to regulate the immune cell trafficking to tumor sites and, therefore, the establishment of an anti-tumor immune response.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Giulia Vanoni

    Department of Oncology, University of Lausanne - Ludwig Institute for Cancer Research, Epalinges, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3199-2412

  2. Giuseppe Ercolano

    Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
    Competing interests
    The authors declare that no competing interests exist.

  3. Simona Candiani

    Department of Earth Science, Environment and Life, University of Genova, Genova, Italy
    Competing interests
    The authors declare that no competing interests exist.

  4. Mariangela Rutigliani

    Department of Laboratory and Service, Histological and Anatomical Pathology, E.O. Galliera Hospital, Genova, Italy
    Competing interests
    The authors declare that no competing interests exist.

  5. Mariangela Lanata

    Department of Laboratory and Service, Histological and Anatomical Pathology,, E.O. Galliera Hospital, Genova, Italy
    Competing interests
    The authors declare that no competing interests exist.

  6. Laurent Derré

    Department of Urology, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
    Competing interests
    The authors declare that no competing interests exist.

  7. Emanuela Marcenaro

    Department of Experimental Medicine and Centre of Excellence for Biomedical Research, University of Genova, Genova, Italy
    Competing interests
    The authors declare that no competing interests exist.

  8. Pascal Schneider

    Department of Biochemistry, University of Lausanne - Ludwig Institute for Cancer Research, Epalinges, Switzerland
    Competing interests
    The authors declare that no competing interests exist.

  9. Pedro Romero

    Department of Oncology, University of Lausanne, Epalinges, Switzerland
    Competing interests
    The authors declare that no competing interests exist.

  10. Camilla Jandus

    Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
    For correspondence
    camilla.jandus@unige.ch
    Competing interests
    The authors declare that no competing interests exist.

  11. Sara Trabanelli

    Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
    For correspondence
    sara.trabanelli@unige.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8648-1324

Funding

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (PRIMA PR00P3_179727)

  • Camilla Jandus

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (FNS 31003A_156469)

  • Pedro Romero

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030A_176256)

  • Pascal Schneider

Compagnia di San Paolo (2019.866)

  • Emanuela Marcenaro

Compagnia di San Paolo (2019.866)

  • Simona Candiani

Associazione Italiana per la Ricerca sul Cancro (AIRC 5x1000-21147)

  • Emanuela Marcenaro

Associazione Italiana per la Ricerca sul Cancro (AIRC 5x1000-21147)

  • Simona Candiani

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Vincenzo Cerullo, University of Helsinki, Finland

Version history

  1. Received: May 12, 2020
  2. Accepted: February 5, 2021
  3. Accepted Manuscript published: February 8, 2021 (version 1)
  4. Version of Record published: February 18, 2021 (version 2)

Copyright

© 2021, Vanoni et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 861
    views
  • 124
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Giulia Vanoni
  2. Giuseppe Ercolano
  3. Simona Candiani
  4. Mariangela Rutigliani
  5. Mariangela Lanata
  6. Laurent Derré
  7. Emanuela Marcenaro
  8. Pascal Schneider
  9. Pedro Romero
  10. Camilla Jandus
  11. Sara Trabanelli
(2021)
Human primed ILCPs support endothelial activation through NF-κB signaling
eLife 10:e58838.
https://doi.org/10.7554/eLife.58838

Share this article

https://doi.org/10.7554/eLife.58838

Categories and tags

Research organism

Further reading

    1. Cancer Biology

    Recording and classifying MET receptor mutations in cancers

    Célia Guérin, David Tulasne
    Review Article

    Tyrosine kinase inhibitors (TKI) directed against MET have been recently approved to treat advanced non-small cell lung cancer (NSCLC) harbouring activating MET mutations. This success is the consequence of a long characterization of MET mutations in cancers, which we propose to outline in this review. MET, a receptor tyrosine kinase (RTK), displays in a broad panel of cancers many deregulations liable to promote tumour progression. The first MET mutation was discovered in 1997, in hereditary papillary renal cancer (HPRC), providing the first direct link between MET mutations and cancer development. As in other RTKs, these mutations are located in the kinase domain, leading in most cases to ligand-independent MET activation. In 2014, novel MET mutations were identified in several advanced cancers, including lung cancers. These mutations alter splice sites of exon 14, causing in-frame exon 14 skipping and deletion of a regulatory domain. Because these mutations are not located in the kinase domain, they are original and their mode of action has yet to be fully elucidated. Less than five years after the discovery of such mutations, the efficacy of a MET TKI was evidenced in NSCLC patients displaying MET exon 14 skipping. Yet its use led to a resistance mechanism involving acquisition of novel and already characterized MET mutations. Furthermore, novel somatic MET mutations are constantly being discovered. The challenge is no longer to identify them but to characterize them in order to predict their transforming activity and their sensitivity or resistance to MET TKIs, in order to adapt treatment.

    1. Cancer Biology
    2. Genetics and Genomics

    Convergent epigenetic evolution drives relapse in acute myeloid leukemia

    Kevin Nuno, Armon Azizi ... Ravindra Majeti
    Research Article

    Relapse of acute myeloid leukemia (AML) is highly aggressive and often treatment refractory. We analyzed previously published AML relapse cohorts and found that 40% of relapses occur without changes in driver mutations, suggesting that non-genetic mechanisms drive relapse in a large proportion of cases. We therefore characterized epigenetic patterns of AML relapse using 26 matched diagnosis-relapse samples with ATAC-seq. This analysis identified a relapse-specific chromatin accessibility signature for mutationally stable AML, suggesting that AML undergoes epigenetic evolution at relapse independent of mutational changes. Analysis of leukemia stem cell (LSC) chromatin changes at relapse indicated that this leukemic compartment underwent significantly less epigenetic evolution than non-LSCs, while epigenetic changes in non-LSCs reflected overall evolution of the bulk leukemia. Finally, we used single-cell ATAC-seq paired with mitochondrial sequencing (mtscATAC) to map clones from diagnosis into relapse along with their epigenetic features. We found that distinct mitochondrially-defined clones exhibit more similar chromatin accessibility at relapse relative to diagnosis, demonstrating convergent epigenetic evolution in relapsed AML. These results demonstrate that epigenetic evolution is a feature of relapsed AML and that convergent epigenetic evolution can occur following treatment with induction chemotherapy.

    1. Cancer Biology
    2. Cell Biology

    Early recovery of proteasome activity in cells pulse-treated with proteasome inhibitors is independent of DDI2

    Ibtisam Ibtisam, Alexei F Kisselev
    Short Report

    Rapid recovery of proteasome activity may contribute to intrinsic and acquired resistance to FDA-approved proteasome inhibitors. Previous studies have demonstrated that the expression of proteasome genes in cells treated with sub-lethal concentrations of proteasome inhibitors is upregulated by the transcription factor Nrf1 (NFE2L1), which is activated by a DDI2 protease. Here, we demonstrate that the recovery of proteasome activity is DDI2-independent and occurs before transcription of proteasomal genes is upregulated but requires protein translation. Thus, mammalian cells possess an additional DDI2 and transcription-independent pathway for the rapid recovery of proteasome activity after proteasome inhibition.